Christopher James Frankenfield

Insider Reports History

Location
Waltham, MA
Signature
/s/ Kevin Brennan, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher James Frankenfield:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Xilio Therapeutics, Inc. Chief Financial Officer Restricted Stock Units 58.1K $57.2K $0.98 01 Jan 2025 Direct
Xilio Therapeutics, Inc. Chief Financial Officer Common stock 12.4K $12.2K $0.98 02 Jan 2025 Direct
Xilio Therapeutics, Inc. Chief Financial Officer Stock Option (right to buy) 300K 21 Nov 2025 Direct

Insider Reports Filed by Christopher James Frankenfield

Symbol Company Period Transactions Value $ Form Type Role Filing Time
XLO Xilio Therapeutics, Inc. 21 Nov 2025 17 $0 4 Chief Financial Officer 25 Nov 2025, 16:10
XLO Xilio Therapeutics, Inc. 15 Apr 2025 1 $0 4 Chief Financial Officer 16 Apr 2025, 16:30
XLO Xilio Therapeutics, Inc. 01 Jan 2025 4 -$6.84K 4 Chief Financial Officer 03 Jan 2025, 16:15
XLO Xilio Therapeutics, Inc. 03 Aug 2024 1 $0 4 Chief Operating Officer 06 Aug 2024, 20:00
XLO Xilio Therapeutics, Inc. 01 May 2024 1 $0 4 CHIEF OPERATING OFFICER 03 May 2024, 16:10
XLO Xilio Therapeutics, Inc. 01 Jan 2024 1 $0 4 CHIEF OPERATING OFFICER 03 Jan 2024, 16:38
XLO Xilio Therapeutics, Inc. 16 Aug 2023 1 $0 4 CHIEF OPERATING OFFICER 18 Aug 2023, 21:40
XLO Xilio Therapeutics, Inc. 03 Aug 2023 1 $0 4 Chief Operating Officer 07 Aug 2023, 16:12
XLO Xilio Therapeutics, Inc. 03 Aug 2023 0 $0 3 Chief Operating Officer 07 Aug 2023, 16:09